1 The risk for any
adverse birth outcome was lower among infants exposed fr
2 ng 2005 to 2010 and estimated PTBs and other
adverse birth outcomes for infants borne by non-Hispanic
3 esidential area, showing that an increase in
adverse birth outcomes is observed with very high levels
4 ing factors, such as substance use, previous
adverse birth outcomes, and demographic factors.
5 cidence of malaria, parasite prevalence, and
adverse birth outcomes.
6 cal associations between arginine intake and
adverse birth outcomes.
7 Major
adverse cardiac and cardiovascular event rate at 30 days
8 In-hospital major
adverse cardiac and cerebral events occurred in 2.0% in
9 disease in the MM population as well as the
adverse cardiac and vascular effects of MM itself.
10 his study recorded the occurrence of a major
adverse cardiac event (MACE) assessed as the composite o
11 o significant differences in composite major
adverse cardiac event scores at each time point up to 48
12 total mortality or hospitalization for major
adverse cardiac events (aHR: 0.30; 95% CI: 0.12 to 0.78)
13 n strategy with respect to the rate of major
adverse cardiac events at 12 months.
14 The primary end point was major
adverse cardiac events defined as all-cause mortality, h
15 Major
adverse cardiac events occurred in 1.1% and 4.2% of ever
16 end points included clinical outcomes (major
adverse cardiac events), use of healthcare resources, an
17 ional potential to counteract the effects of
adverse cardiac remodeling, thereby improving survival a
18 The primary safety end point was major
adverse cardiac, cerebrovascular, and renal events at 1
19 of systemic atherosclerosis with associated
adverse cardiovascular and limb events.
20 Secondary outcomes included major
adverse cardiovascular events (eg, nonfatal myocardial i
21 owed for incident type 1 and T2MI, and major
adverse cardiovascular events (MACE, a composite of all-
22 ess than 2 mg/L had a 25% reduction in major
adverse cardiovascular events (multivariable adjusted ha
23 ary heart disease by 27% (P=0.033) and major
adverse cardiovascular events by 25% (P=0.037) during th
24 e, acarbose did not reduce the risk of major
adverse cardiovascular events, but did reduce the incide
25 the effects of canakinumab on rates of major
adverse cardiovascular events, cardiovascular mortality,
26 to 2.97), and 3.09 (0.96 to 8.78) for major
adverse cardiovascular events, hospitalizations, and vas
27 sis is to compare all-cause mortality, major
adverse cardiovascular events, myocardial infarction (MI
28 Secondary outcomes included major
adverse cardiovascular events.
29 diovascular risk factors at target and major
adverse cardiovascular outcomes among patients with T1DM
30 s are independent and additive predictors of
adverse cardiovascular outcomes in coronary artery disea
31 Myocardial fibrosis is linked with
adverse clinical outcomes in adults after tetralogy of F
32 ks to its ability to resist and adapt to the
adverse conditions it encounters upon infection.
33 inactive in the germ-line precursors during
adverse conditions.
34 eptors may inadvertently produce substantial
adverse consequences for cocaine addiction.
35 ther PAC can successfully compensate for the
adverse consequences of a complicated postoperative reco
36 st have little chance of inducing unintended
adverse consequences.
37 se and not merely by association with other
adverse cytogenetic features.
38 assays have demonstrated an association with
adverse disease outcomes, such as urethritis or nongonoc
39 ion of genetic variants associated with this
adverse drug reaction will further our mechanistic under
40 ams was used to assess treatment completion,
adverse drug reactions, and factors associated with trea
41 duced ocular hypertension (OHT) is a serious
adverse effect of prolonged GC therapy that can lead to
42 r HO-CDI rates; this highlights an important
adverse effect of the PIP/TAZO shortage and the importan
43 n turnover in ATM-depleted cells also has an
adverse effect on the DNA base excision repair pathway,
44 The most common
adverse effect was decreased blood calcium (68.9% vs 59.
45 hich clozapine may act to cause this serious
adverse effect.
46 ir therapeutic effects (analgesia) and their
adverse effects (addiction and overdose).
47 achieving statistically significantly lower
adverse effects (change in breast appearance [p=0.007 fo
48 t, and clinical assessments recorded similar
adverse effects after reduced-dose or partial-breast rad
49 AES may exert context-specific beneficial or
adverse effects in patients with critical illness.
50 We observe similar
adverse effects in sanitation, shelter, and health care
51 A1 ubiquitin-deficient mutants inhibited the
adverse effects of Abeta on the surface expression of AM
52 Furthermore, the
adverse effects of ATB2 cells on glucose homeostasis wer
53 None of the studies reported
adverse effects of C. asiatica.
54 rotect human health and the environment from
adverse effects of mercury.
55 These
adverse effects of tPA were ameliorated in PPK (Klkb1)-d
56 Steroid hormones produce
adverse effects on biota as well as bioaccumulation in f
57 Obesity has
adverse effects on cardiovascular hemodynamics and cardi
58 and maintenance resulted in initially small
adverse effects on consumers, but ultimately led to popu
59 for the effects of sildenafil that, through
adverse effects on mitochondrial function and endoplasmi
60 vioral tests showed no significant long-term
adverse effects on sciatic nerve functions.
61 The 6 week long stimulation had no residual
adverse effects on the electrophysiologic characteristic
62 s and may contribute toward infusion-related
adverse effects such as allergic responses.
63 one of the key players in diabetes-mediating
adverse effects to the neuronal and vascular components
64 ose used for recombination induction, caused
adverse effects to the testis and to the reproductive en
65 ts; however, some GBCAs have a small risk of
adverse effects, including nephrogenic systemic fibrosis
66 d NK cells after haploidentical HSCT without
adverse effects, increased GVHD, or higher mortality, an
67 , without any clear signal of any unexpected
adverse effects.
68 elagolix were associated with hypoestrogenic
adverse effects.
69 ding key information to limit immune-related
adverse effects.
70 igh-dose prednisolone with potentially fewer
adverse effects.
71 ectiveness, as well as clinical outcomes and
adverse effects.
72 ng mortality rates, neurologic outcomes, and
adverse effects.
73 % to 29% of patients reported opioid-induced
adverse effects.
74 is needed to assess longer-term efficacy and
adverse effects.
75 r dystrophy but are accompanied by prominent
adverse effects.
76 um, which exhibits excellent adaptability to
adverse environments, K(+) concentration remains at a re
77 hat dictates cell fate following exposure to
adverse environments.
78 At least one emergent
adverse event (AE) was recorded for 79/190 (41x6%) in th
79 lpatasvir-voxilaprevir therapy because of an
adverse event (AE).
80 Overall, 71% of patients suffered an
adverse event (AE); the majority of these were grades 1
81 tional cohort study, we compared time to any
adverse event (primary outcome); serious or nonserious e
82 One serious
adverse event (transient atrial fibrillation) occurred i
83 from mechanical ventilation is viewed as an
adverse event in ICUs.
84 The most common serious
adverse event in the active surveillance group was myoca
85 3 patients) was the most frequently reported
adverse event in the alternative ACT group.
86 Adverse event incidences in the 24-week placebo-controll
87 In these patients, no
adverse event occurred when clinical pathways were corre
88 ondary end points included anatomic patency,
adverse event rate, and return to operating room within
89 t treatments were not associated with higher
adverse event rates than placebo.
90 The Food and Drug Administration
Adverse Event Reporting System (FAERS) remains the prima
91 One
adverse event unrelated to study devices occurred during
92 , whereas the most common non-haematological
adverse event was hypokalaemia (25 [17%] of 147 vs 22 [1
93 The most common
adverse event was pain related to surgical incision or p
94 ed antitoxin (n = 193), 23 (12%) reported an
adverse event, including rash, fever, serum sickness, an
95 to high-frequency hearing loss, an expected
adverse event, was documented in all participants.
96 370 patients had a serious treatment-related
adverse event.
97 , and no participants withdrew because of an
adverse event.
98 -101 reported at least one treatment-related
adverse event.
99 Frequent severe
adverse events (>4% difference from placebo) were diarrh
100 dies reported low rates of death and serious
adverse events (0% to 1.25%) in nontransported patients
101 Before ASCT,
adverse events (AEs) occurred in 98% of patients, mostly
102 Daily temperatures and
adverse events (AEs) were recorded days 1 to 42 postvacc
103 Safety measures included
adverse events (AEs), clinical laboratory tests, vital s
104 Grade >/=3
adverse events (AEs; >5%) included anemia, pneumonia, an
105 the placebo group; the most frequent serious
adverse events (affecting >/=2% of patients) were elevat
106 Treatment-related
adverse events (any grade) prompted treatment discontinu
107 Adverse events (eg, lethargy, diarrhoea, rash, and nause
108 23 (22%) patients died because of
adverse events (mainly from sepsis, eight [8%]; and pneu
109 even patients (61%) experienced drug-related
adverse events (mostly grade 1-2); none discontinued tre
110 and one patient died from treatment-related
adverse events (myositis in addition to grade 3 thyroidi
111 Serious
adverse events (regardless of relation to study treatmen
112 primary outcomes were treatment failure and
adverse events 14 days after diagnosis.
113 ney, leading to dose-limiting toxicities and
adverse events affecting quality of life.
114 The most common treatment-related
adverse events among the 54 patients were hypercholester
115 The primary outcome was the incidence of
adverse events among vaccine and placebo recipients thro
116 hic angiography and strongly associated with
adverse events among women.
117 al, body region scanned, type, dose, related
adverse events and route of administration of sedatives
118 ATION: Despite an increase in haematological
adverse events and second primary malignancies, lenalido
119 Adverse events are defined with Valve Academic Research
120 370 patients died from non-treatment-related
adverse events associated with death, and one patient di
121 However, the
adverse events associated with smoking limit its clinica
122 No other serious
adverse events attributable to angiotensin II were repor
123 Adverse events attributable to PHS cost an additional $6
124 arge differences in risk of systemic serious
adverse events between these two anti-VEGF drugs; i.e.,
125 n in-hospital AKI and risk of post-discharge
adverse events by AKIN stage.
126 Adverse events comprised CVD death, myocardial infarctio
127 tudy drug, which were grade 2 neurocognitive
adverse events comprising slowed speech and mentation an
128 pneumonia, five [5%]); four deaths were from
adverse events deemed treatment-related (pneumonia, two
129 Rates of grade 3-4
adverse events did not differ among regimens (P = .37).
130 Overall and serious
adverse events did not differ between the flecainide and
131 The overall rate of serious
adverse events did not differ between treatment groups,
132 er, medullary thyroid carcinoma, and serious
adverse events did not differ significantly between the
133 The annual frequency of
adverse events did not occur more frequently with cumula
134 Incidence of treatment-related
adverse events did not seem to be associated with dose a
135 There were no
adverse events either immediately or at 2-week follow-up
136 the transition from desired drug effects to
adverse events following administration of either therap
137 Common
adverse events in patients treated at the MTD (n = 57) i
138 febrile neutropenia (27 [17%] of 155 serious
adverse events in patients who received doxorubicin and
139 ived doxorubicin and 15 [12%] of 130 serious
adverse events in patients who received gemcitabine and
140 We recorded
adverse events in ten (34%) of 29 patients given twice-w
141 Ocular
adverse events in the aflibercept group included 4 parti
142 than 10 mm Hg greater than baseline; ocular
adverse events in the bevacizumab group included 1 parti
143 The most frequently reported
adverse events in the brexanolone group were dizziness (
144 Exercise-related
adverse events included musculoskeletal injuries.
145 A variety of dermatologic immune-related
adverse events including maculopapular eruption, licheno
146 Drug-related
adverse events occurred in 130 (24%) of 531 participants
147 Minor
adverse events occurred in 22% of patients in the contro
148 Drug-related serious
adverse events occurred in 28 (38%) of 74 patients.
149 Five serious
adverse events occurred in 4 cases (15%), including pulm
150 Adverse events occurred in 51 (48%) of CGM participants
151 s, and only grade 1 (mild) local or systemic
adverse events occurred in both groups.
152 Eight serious
adverse events occurred in each group.
153 een treatment groups, although some specific
adverse events occurred more often in the intensive grou
154 No
adverse events occurred.
155 Serious
adverse events occurring in 5% or more of patients were
156 Serious
adverse events occurring in more than two patients inclu
157 ociated with a higher risk of the well-known
adverse events of fever, rash, and convulsions within th
158 The most common
adverse events of grade 3 or higher during treatment wer
159 Adverse events of grade 3 or higher were reported in 87%
160 The most common
adverse events of grade 3 or worse severity were anaemia
161 Trial withdrawals and
adverse events of rash, dizziness, and dental discolorat
162 There were no serious
adverse events or discontinuations due to adverse events
163 significant differences in local or systemic
adverse events or laboratory abnormalities between the P
164 s, representing 111 (39%) of all 285 serious
adverse events recorded, were febrile neutropenia (27 [1
165 The most common
adverse events reported in the re-treatment ACT group we
166 The most common grade 3-4 haematological
adverse events reported, irrespective of attribution, we
167 [11.1%]) or placebo (32 of 255 [12.5%]); all
adverse events resolved without sequelae.
168 The most common serious
adverse events that occurred through week 24 were anaemi
169 ched for studies in which rates of immediate
adverse events to GBCAs were reported.
170 ed in phase 3 trials), the most common local
adverse events versus placebo within the first 14 days w
171 tients who discontinued treatment because of
adverse events was low (range, 0%-1%).
172 Incidence and severity of
adverse events was mostly similar between groups except
173 Incidence of
adverse events was similar for alirocumab versus control
174 Incidence of
adverse events was similar in all groups (43 [88%] of 49
175 The number of
adverse events was similar regardless of immunisation st
176 The most common serious
adverse events were anaemia (eight [4%]), upper gastroin
177 Adverse events were attributable to 23 (5%) deaths in th
178 Adverse events were common with medications but not with
179 Adverse events were defined as fatal or nonfatal aortic
180 he most frequently reported grade 3 or worse
adverse events were diarrhoea (103 [21%] of 488 patients
181 Serious
adverse events were experienced by 35 (18%) patients in
182 Treatment-related
adverse events were generally grade 1 or 2 in severity.
183 Adverse events were generally mild (</= grade 2), with d
184 Thirteen serious
adverse events were identified among recipients of HRV,
185 The most common
adverse events were infective pulmonary exacerbations, c
186 The most common isatuximab-related
adverse events were infusion-associated reactions (IARs)
187 Data on
adverse events were limited, but suggested an increased
188 All the
adverse events were mild or moderate in severity.
189 Adverse events were more frequent with clindamycin (58 o
190 Adverse events were more frequent with tofacitinib than
191 Deaths due to
adverse events were observed in 27 (12%) patients in the
192 Fewer grade 3 and 4 treatment-related
adverse events were observed in patients on nivolumab (1
193 Adverse events were rarely reported.
194 No severe
adverse events were recorded.
195 Adverse events were reported as expected and were simila
196 Grade 3 to 4 treatment-related
adverse events were reported in 38.3% and 61.7% of the p
197 Serious
adverse events were reported in 56 (58%) eltrombopag-tre
198 Serious
adverse events were reported in 64 (22%) of 288 patients
199 No severe vaccine-related
adverse events were reported.
200 Most
adverse events were respiratory, and in some patients it
201 Adverse events were similar between the subgroups.
202 The rates of renal
adverse events were similar in the liraglutide group and
203 The most common
adverse events were skin reactions occurring in 49 (48%)
204 The most frequently observed grade 3 and 4
adverse events were transaminase increases (40% alanine
205 The most common grade 3-4
adverse events with a suspected association with long-ac
206 Serious
adverse events within 12 months after injection were see
207 nths, hemodialysis- and chemotherapy-related
adverse events, and death.
208 r 92% of the 48 hours cooling period without
adverse events, and was lower than the controls (34.35 d
209 of blood-product use, infection, and serious
adverse events, as well as 28-day mortality, did not dif
210 26 (39%) of 44 patients had grade 3
adverse events, but no grade 4 events were reported.
211 secondary objectives included evaluation of
adverse events, changes in sexual quality of life using
212 outcome mainly relies on the declaration of
adverse events, identification of their predictors, self
213 nd recognising, responding to and disclosing
adverse events, including errors and near misses.
214 Seven (44%) of 16 patients had serious
adverse events, most of which were related to the underl
215 Frequency of
adverse events, mostly mild self-limited joint and back
216 recurrence or new breast cancer, intolerable
adverse events, or consent withdrawal occurred.
217 occurred because of adverse events, serious
adverse events, or deaths in patients who received lanad
218 Rate of
adverse events, quality of life, and patient satisfactio
219 The three most common serious
adverse events, representing 111 (39%) of all 285 seriou
220 No discontinuations occurred because of
adverse events, serious adverse events, or deaths in pat
221 is needed to optimize its dosing to minimize
adverse events, such as peripheral neuropathy.
222 Safety was assessed on the basis of
adverse events, which were graded according to the Commo
223 Major cardiovascular
adverse events-free survival was worse in patients with
224 The main safety measure was
adverse events.
225 rding to the Common Terminology Criteria for
Adverse Events.
226 ce of death, sudden death, and other cardiac
adverse events.
227 mal peak flow, antibiotic use, or nonserious
adverse events.
228 us adverse events or discontinuations due to
adverse events.
229 fety assessments included treatment-emergent
adverse events.
230 crease in cardiovascular and cerebrovascular
adverse events.
231 up discontinued the trial regimen because of
adverse events.
232 ade 1-2); none discontinued treatment due to
adverse events.
233 nt with oral morphine, with similar rates of
adverse events.
234 perglycemia among the most common high grade
adverse events.
235 the intervention was high and there were no
adverse events.
236 creased risk of complicated appendicitis and
adverse events.
237 RCE was well tolerated with no
adverse events.Twice daily RCE intake over 1 y potently
238 Six (3%) patients had 11 serious
adverse events: one (2%) patient in the placebo group, t
239 Nine patients died from
adverse events; five of these deaths were judged to be r
240 12 patients reported serious
adverse events; haemolysis and pyrexia were the most com
241 Two (1%) of 166 patients had serious
adverse events; neither were considered related to study
242 %) patients had 11 grade 3 treatment-related
adverse events; no single event occurred in more than on
243 Fifteen patients experienced grade 3 to 4
adverse events; the most common were fluid retention and
244 Adverse experiences in childhood and adolescence, define
245 V) infection in pregnancy is associated with
adverse fetal outcomes, such as microcephaly and other c
246 nancy was associated with the lowest risk of
adverse fetal outcomes.
247 was the most frequently reported CXL-related
adverse finding.
248 cimimetic could improve adherence and reduce
adverse gastrointestinal effects.
249 e efficiency of targeted mutagenesis and the
adverse generation of off-target mutations vary greatly
250 S) enrolled in the MATRIX-Access (Minimizing
Adverse Haemorrhagic Events by Transradial Access Site a
251 stent relationship between aneurysm size and
adverse HCM-related events.
252 s estrogenic activity and is associated with
adverse health effects in humans and wildlife.
253 the troposphere, understanding mechanisms of
adverse health effects through inhalation exposure is cr
254 Many
adverse health outcomes are associated with obstructive
255 n disruptions are implicated in a variety of
adverse health outcomes, including substance use disorde
256 eather events that have been associated with
adverse health outcomes.
257 plication which has short-term and long-term
adverse health ramifications for both women and their ch
258 treated from 1990 to 1999), those reporting
adverse health status did not decrease by treatment deca
259 No toxicity or
adverse immune consequences of vector administration are
260 ovide vital information on the likelihood of
adverse impacts during extreme ENSO events.
261 orically been associated with a high risk of
adverse ischemic events, but there is a paucity of conte
262 ed with a considerably higher risk of 2-year
adverse ischemic events, with HPR conferring similar ris
263 Certain variants may moderate the effect of
adverse life events on the risk of GAD.
264 oved infarct size, LV ejection fraction, and
adverse LV remodeling, changes associated with decreased
265 tment was associated with the lowest risk of
adverse maternal outcomes, whereas the use of LMWH throu
266 ine's antidepressant efficacy, suggesting an
adverse metabolic state.
267 tenuated strains, can still show substantial
adverse or lethal actions in the brain.
268 n during 2013-14 influenza season attenuated
adverse outcome among adults that were hospitalized with
269 associated with increased risk of composite
adverse outcome independently of other risk factors.
270 g the first year of therapy, associated with
adverse outcome.
271 ERT promoter mutations alone did not predict
adverse outcomes (P = 0.50), but the presence of TERT pr
272 o prevent acute kidney injury and associated
adverse outcomes after angiography without definitive ev
273 inical animal testing often fails to predict
adverse outcomes arising from sequential, multi-organ me
274 harm and violent offending, respectively, as
adverse outcomes at ages 15-35 years.
275 (MIDP) and identify actual risk factors for
adverse outcomes compared with open distal pancreatectom
276 e in the volume-outcome model, risk-adjusted
adverse outcomes declined, including mortality (3.57% to
277 ) and cardiac troponin I are associated with
adverse outcomes in stable kidney transplant recipients.
278 low hemoglobin concentrations, the link with
adverse outcomes is more evident when hemoglobin concent
279 rs are serious, avoidable, costly and common
adverse outcomes of healthcare.
280 sed exposure might translate to sex-specific
adverse outcomes such as behavioral deficits is a possib
281 We calculated hazard ratios for 1-year
adverse outcomes, including mortality, readmission, and
282 sports participation may be associated with
adverse outcomes, particularly at the elite level.
283 ronic kidney disease and are associated with
adverse outcomes.
284 ent hyperglycemia is common and is linked to
adverse patient outcomes.
285 elective hernia repair at increased risk for
adverse postoperative events.
286 Panic disorder and GAD do not contribute to
adverse pregnancy complications.
287 urning of biomass fuels has been linked with
adverse pregnancy outcomes such as low birth weight, sti
288 increases globally, monitoring for potential
adverse pregnancy outcomes will be crucial.
289 d complex disease that is associated with an
adverse prognosis.
290 lerated the PET/MRI examination well, and no
adverse reactions to (18)F-FTC-146 were reported.
291 Adverse reactions to oral azoles, drug interactions, and
292 lly respond to the desensitization protocol,
adverse reactions were minor and responded to treatment
293 mal necrolysis (SJS/TEN) are rare but severe
adverse reactions with high mortality.
294 broblast-specific Smad3 loss had accentuated
adverse remodeling after reperfused infarction and exhib
295 ritis or nongonococcal urethritis in men and
adverse reproductive sequelae in women-for example, cerv
296 The incidence of
adverse sedation outcomes varied significantly with type
297 In adults, high blood pressure (BP),
adverse serum lipids, and smoking associate with cogniti
298 e serious problem of drug resistance and the
adverse side effect profiles of many TB drugs, further i
299 ents to reduce the risk of radiation-related
adverse systemic effects.
300 A could be safely used as an antidote during
adverse therapeutic modulation of hemostasis.